A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

ABSTRACT: In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of patients treated with initial immunochemotherapy. There is currently a need to define parsimonious clinical models for trial stratification and to add on biomolecular factors. Here, we confirmed the validity of both the follicular lymphoma international prognostic index (FLIPI) and the FLIPI2 in the large prospective PRIMA trial cohort of 1135 patients treated with initial R-chemotherapy ± R maintenance. Furthermore, we developed a new prognostic tool comprising only 2 simple parameters (bone marrow involvement and β₂-microglobulin [β₂m]) to predict progression-free survival (PFS). The final simplified score, called the PRIMA-PI (PRIMA-prognostic index), comprised 3 risk catego

SUBMITTER: Bachy E 

PROVIDER: S-EPMC6034646 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature